| Recurrent bone marrow aplasia secondary to nilotinib in a patient with chronic myeloid leukemia: A case report. | |
| | |
MedLine Citation:
|
PMID: 22399151 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Nilotinib is a potent tyrosine kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL), which has been approved as front-line therapy for newly diagnosed chronic myeloid leukemia in chronic phase and as second-line therapy after imatinib failure in chronic or accelerated phase chronic myeloid leukemia. Tyrosine kinase inhibitors have been associated with myelosuppression and grade 3 or grade 4 cytopenias are not uncommon in chronic myeloid leukemia patients treated with these drugs. There are a few reports of imatinib-associated bone marrow aplasia, but to our knowledge only one reported case of bone marrow aplasia associated with nilotinib. Herein, we report a 49-year-old male patient with chronic phase chronic myeloid leukemia, who developed severe bone marrow aplasia due to nilotinib. Possible mechanisms for this significant adverse drug reaction are discussed along with a review of literature. |
| | |
Authors:
|
Prathima Prodduturi; Anamarija M Perry; Patricia Aoun; Dennis D Weisenburger; Mojtaba Akhtari |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-3-7 |
Journal Detail:
|
Title: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners Volume: - ISSN: 1477-092X ISO Abbreviation: - Publication Date: 2012 Mar |
Date Detail:
|
Created Date: 2012-3-8 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9511372 Medline TA: J Oncol Pharm Pract Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pd(ii)-catalyzed direct C5-arylation of azole-4-carboxylates through double C-H bond cleavage.
Next Document: Postoperative Hungry Bone Syndrome in Patients with Secondary Hyperparathyroidism of Renal Origin.